1072 Results for "

active targeting

" in MedChemExpress (MCE) Product Catalog:
Products (1072)

1072 Results for "active targeting" in MCE Product Catalog:

213
213 Publications Verification
Cat. No.: HY-16658
CAS No.: 187389-52-2
Synonyms: Z-Val-Ala-Asp(OMe)-FMK
Target:  

Caspase

Research Areas:  

Cancer

Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) is a cell-permeable and irreversible pan-caspase inhibitor . Z-VAD(OMe)-FMK is an ubiquitin carboxy-terminal hydrolase L1 (UCHL1) inhibitor. Z-VAD(OMe)-FMK irreversibly modifies UCHL1 by targeting the active site of UCHL1 .
loading...
    loading...
166
166 Cited Publications
Cat. No.: HY-10087A1
CAS No.: 1093851-28-5
Synonyms: ABT-263 dihydrochloride
Navitoclax dihydrochloride (ABT-263 dihydrochloride) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax dihydrochloride triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax dihydrochloride alleviates fibrosis and induces thrombocytopenia. Navitoclax dihydrochloride exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax dihydrochloride can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases .
loading...
    loading...
117
117 Cited Publications
Cat. No.: HY-138687
CAS No.: 2628280-40-8
Purity:  99.74%
Synonyms: PF-07321332
Target:  

SARS-CoV

Research Areas:  

Infection Inflammation/Immunology

Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CL PRO) inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research .
loading...
    loading...
100
100 Cited Publications
Cat. No.: HY-10331
CAS No.: 755037-03-7
Purity:  99.93%
Synonyms: BAY 73-4506
Research Areas:  

Cancer

Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .
loading...
    loading...
100
100 Cited Publications
Cat. No.: HY-10331A
CAS No.: 1019206-88-2
Purity:  99.96%
Synonyms: BAY 73-4506 monohydrate
Research Areas:  

Cancer

Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .
loading...
    loading...
82
82 Cited Publications
Cat. No.: HY-10971
CAS No.: 1028486-01-2
Purity:  99.36%
Synonyms: MLN 8237
Research Areas:  

Cancer

Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
loading...
    loading...
59
59 Cited Publications
Cat. No.: HY-12047
CAS No.: 943319-70-8
Purity:  99.67%
Synonyms: AP24534
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively .
loading...
    loading...
59
59 Cited Publications
Cat. No.: HY-108766
CAS No.: 1114544-31-8
Purity:  99.76%
Synonyms: AP24534 hydrochloride
Research Areas:  

Infection Cancer

Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively .
loading...
    loading...
41
41 Cited Publications
Cat. No.: HY-12215
CAS No.: 1454846-35-5
Purity:  99.92%
Synonyms: PF-06463922
Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive ROS1/ALK inhibitor with anticancer activity. Lorlatinib has Kis of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK L1196M, respectively. Lorlatinib targets to EML4-ALK, and inhibits ALK phosphorylation with IC50s of 15-43 nM (ALK L1196), 14-80 nM (ALK G1269A), 38-50 nM (ALK 1151Tins), 77-113 nM (ALK G1202R), respectively .
loading...
    loading...
40
40 Cited Publications
Cat. No.: HY-10230
CAS No.: 120685-11-2
Purity:  99.91%
Synonyms: PKC412; CGP 41251
Research Areas:  

Cancer

Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-17600
CAS No.: 1420477-60-6
Synonyms: Calquence; ACP-196
Target:  

Btk

Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib can be used for CLL research . Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-15283
CAS No.: 113665-84-2
Purity:  99.13%
Synonyms: Clopidogrelum
Target:  

P2Y Receptor

Research Areas:  

Cardiovascular Disease Cancer

Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-103490
CAS No.: 1111556-37-6
Purity:  99.41%
Synonyms: EDHS-206
Target:  

MAP3K Apoptosis

Takinib (EDHS-206) is an orally active and selective TAK1 inhibitor (IC50=9.5 nM), more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib is an inhibitor of autophosphorylated TAK1 that non-competitively binds within the ATP binding pocket. Takinib induces apoptosis following TNFα stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. Takinib is also a P. falciparum protein kinase 9 (PfPK9) inhibitor (KD(app) of 0.46 μM) .
loading...
    loading...
25
25 Cited Publications
Cat. No.: HY-13032B
CAS No.: 1895049-20-3
Purity:  97.04%
Synonyms: GSK 525762C; I-BET 762 besylate
Research Areas:  

Cancer

Molibresib besylate (GSK 525762C; I-BET 762 besylate) is an orally active pan-BET inhibitor that targets and binds to BRD2, BRD3, BRD4 and BRDT. By competitively occupying acetylated lysine binding sites, Molibresib besylate disrupts the interaction between BET proteins and chromatin, thereby effectively inhibiting MYC expression and target gene transcription. Molibresib besylate exhibits broad antiproliferative activity, which not only inhibits cancer cell growth and induces growth arrest, but also downregulates mitosis-related genes and upregulates the level of p-ERK1/2. When combined with MEK inhibitors, Molibresib besylate shows a significant synergistic effect, reduces tumor burden in mouse models of leukemia, modulates the immune microenvironment and prolongs survival. Molibresib besylate is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer and various advanced refractory solid tumors .
loading...
    loading...
22
22 Cited Publications
Cat. No.: HY-15233
CAS No.: 917389-32-3
Purity:  99.96%
Synonyms: AIC246; MK-8228
Target:  

CMV

Research Areas:  

Infection Cancer

Letermovir (AIC246) is a potent inhibitor of CMV, which targets the viral terminase complex and remains active against virus resistant to DNA polymerase inhibitors.
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-Y1750
CAS No.: 151-18-8
Synonyms: BAPN
β-Aminopropionitrile (BAPN) is a specific, irreversible and orally active lysyl oxidase (LOX) inhibitor. β-Aminopropionitrile targets the active site of LOX or LOXL isoenzymes. β-Aminopropionitrile can be used for the study of obesity .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-Y1750A
CAS No.: 646-03-7
Synonyms: BAPN hydrochloride
β-Aminopropionitrile (BAPN) hydrochloride is a specific, irreversible and orally active lysyl oxidase (LOX) inhibitor. β-Aminopropionitrile hydrochloride targets the active site of LOX or LOXL isoenzymes .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-10423
CAS No.: 936890-98-1
Purity:  99.95%
Synonyms: ASP7486
Target:  

mTOR Autophagy

Research Areas:  

Cancer

OSI-027 (ASP7486) is a potent, selective, orally active and ATP-competitive mTOR kinase activity inhibitor with an IC50 of 4 nM. OSI-027 targets both mTORC1 and mTORC2 with IC50s of 22 nM and 65 nM, respectively .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-B0539
CAS No.: 100643-71-8
Synonyms: Sch34117
Desloratadine (Sch34117) is an orally active and selective H1 receptor antagonist (Ki=0.9 nM) with anti-inflammatory and anti-allergic activities. Desloratadine inhibits the release of histamine and LTC4 from human basophils and targets the regulatory signals of IL-4 and IL-13 production in basophils. Desloratadine significantly alleviates SAR symptoms in patients with concurrent asthma and can be used in the study of seasonal allergic rhinitis and chronic idiopathic urticaria .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-112005
CAS No.: 4004-05-1
Purity:  98.80%
Synonyms: Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine
DOPE (Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) is an orally active inhibitor of ferroptosis with anti-inflammatory and intestinal barrier maintenance activities. DOPE regulates the expression of ACSL4, SLC7A11 and GPX4 to restore the redox system balance, thereby reducing the levels of lipid peroxides, iron ions and intestinal inflammatory factors (IL-1β and IL-6). DOPE promotes the migration and proliferation of intestinal epithelial cells and increases the level of tight junction proteins; it also destabilizes endosomal membranes, mediates the conjugation of RVG peptides with mesenchymal stem cell-derived exosomes to enhance brain targeting. DOPE can be applied to research related to neonatal necrotizing enterocolitis and Alzheimer's disease .
loading...
    loading...